SUBSIDIARY #5
DrugDiscovery @LPBI Group
Team Profile
Team Profile: DrugDiscovery @LPBI Group – A BioTech Start Up submitted for Funding Competition to MassChallenge Boston 2016 Accelerator
From: MassChallenge <contact@masschallenge.org>
Reply-To: <contact@masschallenge.org>
Date: Saturday, April 2, 2016 at 3:17 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: MC Update – Applications Close
Click to Browse the 2016 Startup Applicants
We are DrugDiscovery@LPBI Group – Boston 2016 – Health/Life Sciences
– Three Indications:
- Diabetes – A Combination Drug Therapy to induce Insulin Production by Pancreatic Beta Cells (PPAR-gamma, Leptin, ..)
- Inflammatory Disorders: Inflammatory Bowel Diseases (IBD) – Crohn’s and Ulcerative Colitis (UC) and Others
- Anti-Cancer Drug Discovery @ LPBI Group’s Research Biotech Businesses
JOINT VENTURES for Intellectual Property Development
JVIP
SBH Sciences, Inc. & LPBI Group’s M3DP, Subsidiary #3
Drug Discovery with 3D BioPrinting
– Diabetes (PPAR-gamma, Leptin, ..) IP: List of Clinical Trials (SJW) – done
– Inflammatory Disorders: IBD – IP: List of anti-Inflammatory in Clinical Trials (Stuart) – done
– Anti-Cancer CAR-T – IP: Immune-Oncology: List of Clinical Trials (SJW) – work-in-progress
Drug Delivery System – One solution for many agents for many indications
– Prof. Kost, BGU – License Options
(BioEngineering, 2008 article, See Bob Langer as co-author in References)
Stem Cell Transformation
– Adipose Cells to Pancreatic Beta Cells
– Skin Cells to Pancreatic Beta Cells
Gene Editing for Gene Therapies with 3D BioPrinting
– BioMEMS
– Oglionucleotides Chips
– Transposomes
OTHER PRODUCT CONCEPTS
- Dr. Codrington’s Diagnostics Kit for Skin Cancer targeted at US Clinical Medical Labs
- Dr. Pearlman’s Product Concept of a Cell BioFactory: Applications other than 5.2
- Dr. Pearlman’s Product Concept of an Artificial Kidney
This page has the following sub pages.
2012pharmaceutical
sjwilliamspa